vs
Copart（CPRT）与GENMAB A/S（GMAB）财务数据对比。点击上方公司名可切换其他公司
Copart的季度营收约是GENMAB A/S的1.2倍（$1.2B vs $925.0M），GENMAB A/S净利率更高（36.3% vs 35.0%，领先1.4%），GENMAB A/S同比增速更快（18.7% vs 0.7%），Copart自由现金流更多（$427.2M vs $327.0M）
Copart是一家跨国在线车辆拍卖及再营销服务提供商，服务保险、租车、车队、金融公司等各类汽车经销商，业务覆盖美国、加拿大、英国、德国等11个国家。总部位于美国得克萨斯州达拉斯，拥有200多处实体网点，运营总面积超1万英亩的车辆存放场地。
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
CPRT vs GMAB — 直观对比
营收规模更大
CPRT
是对方的1.2倍
$925.0M
营收增速更快
GMAB
高出18.0%
0.7%
净利率更高
GMAB
高出1.4%
35.0%
自由现金流更多
CPRT
多$100.2M
$327.0M
损益表 — Q1 FY2026 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $925.0M |
| 净利润 | $403.7M | $336.0M |
| 毛利率 | — | 93.8% |
| 营业利润率 | 37.3% | 38.9% |
| 净利率 | 35.0% | 36.3% |
| 营收同比 | 0.7% | 18.7% |
| 净利润同比 | 11.5% | 65.5% |
| 每股收益（稀释后） | $0.41 | $5.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPRTGMAB
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.2B | $925.0M | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | $779.0M | ||
| Q1 24 | $1.0B | — |
净利润CPRTGMAB
| Q4 25 | $403.7M | — | ||
| Q3 25 | $396.4M | — | ||
| Q2 25 | $406.6M | $336.0M | ||
| Q1 25 | $387.4M | — | ||
| Q4 24 | $362.1M | — | ||
| Q3 24 | $322.6M | — | ||
| Q2 24 | $382.3M | $203.0M | ||
| Q1 24 | $325.6M | — |
毛利率CPRTGMAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 93.8% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 96.4% | ||
| Q1 24 | — | — |
营业利润率CPRTGMAB
| Q4 25 | 37.3% | — | ||
| Q3 25 | 36.7% | — | ||
| Q2 25 | 37.3% | 38.9% | ||
| Q1 25 | 36.6% | — | ||
| Q4 24 | 35.4% | — | ||
| Q3 24 | 33.6% | — | ||
| Q2 24 | 38.8% | 30.3% | ||
| Q1 24 | 37.2% | — |
净利率CPRTGMAB
| Q4 25 | 35.0% | — | ||
| Q3 25 | 35.2% | — | ||
| Q2 25 | 33.6% | 36.3% | ||
| Q1 25 | 33.3% | — | ||
| Q4 24 | 31.6% | — | ||
| Q3 24 | 30.2% | — | ||
| Q2 24 | 33.9% | 26.1% | ||
| Q1 24 | 31.9% | — |
每股收益（稀释后）CPRTGMAB
| Q4 25 | $0.41 | — | ||
| Q3 25 | $0.40 | — | ||
| Q2 25 | $0.42 | $5.42 | ||
| Q1 25 | $0.40 | — | ||
| Q4 24 | $0.37 | — | ||
| Q3 24 | $0.34 | — | ||
| Q2 24 | $0.39 | $3.13 | ||
| Q1 24 | $0.33 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $9.6B | $5.3B |
| 总资产 | $10.6B | $6.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CPRTGMAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $622.0M | ||
| Q1 24 | — | — |
总债务CPRTGMAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $427.0K | — | ||
| Q1 24 | $453.0K | — |
股东权益CPRTGMAB
| Q4 25 | $9.6B | — | ||
| Q3 25 | $9.2B | — | ||
| Q2 25 | $8.8B | $5.3B | ||
| Q1 25 | $8.3B | — | ||
| Q4 24 | $7.9B | — | ||
| Q3 24 | $7.5B | — | ||
| Q2 24 | $7.2B | $4.4B | ||
| Q1 24 | $6.8B | — |
总资产CPRTGMAB
| Q4 25 | $10.6B | — | ||
| Q3 25 | $10.1B | — | ||
| Q2 25 | $9.7B | $6.5B | ||
| Q1 25 | $9.2B | — | ||
| Q4 24 | $8.9B | — | ||
| Q3 24 | $8.4B | — | ||
| Q2 24 | $8.0B | $5.6B | ||
| Q1 24 | $7.6B | — |
负债/权益比CPRTGMAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $535.3M | $349.0M |
| 自由现金流经营现金流 - 资本支出 | $427.2M | $327.0M |
| 自由现金流率自由现金流/营收 | 37.0% | 35.4% |
| 资本支出强度资本支出/营收 | 9.4% | 2.4% |
| 现金转化率经营现金流/净利润 | 1.33× | 1.04× |
| 过去12个月自由现金流最近4个季度 | $1.4B | — |
8季度趋势，按日历期对齐
经营现金流CPRTGMAB
| Q4 25 | $535.3M | — | ||
| Q3 25 | $438.5M | — | ||
| Q2 25 | $700.9M | $349.0M | ||
| Q1 25 | $178.1M | — | ||
| Q4 24 | $482.3M | — | ||
| Q3 24 | $439.2M | — | ||
| Q2 24 | $496.3M | $438.0M | ||
| Q1 24 | $161.8M | — |
自由现金流CPRTGMAB
| Q4 25 | $427.2M | — | ||
| Q3 25 | $350.8M | — | ||
| Q2 25 | $572.9M | $327.0M | ||
| Q1 25 | $61.5M | — | ||
| Q4 24 | $245.5M | — | ||
| Q3 24 | $301.3M | — | ||
| Q2 24 | $408.5M | $430.0M | ||
| Q1 24 | $38.8M | — |
自由现金流率CPRTGMAB
| Q4 25 | 37.0% | — | ||
| Q3 25 | 31.2% | — | ||
| Q2 25 | 47.3% | 35.4% | ||
| Q1 25 | 5.3% | — | ||
| Q4 24 | 21.4% | — | ||
| Q3 24 | 28.2% | — | ||
| Q2 24 | 36.2% | 55.2% | ||
| Q1 24 | 3.8% | — |
资本支出强度CPRTGMAB
| Q4 25 | 9.4% | — | ||
| Q3 25 | 7.8% | — | ||
| Q2 25 | 10.6% | 2.4% | ||
| Q1 25 | 10.0% | — | ||
| Q4 24 | 20.6% | — | ||
| Q3 24 | 12.9% | — | ||
| Q2 24 | 7.8% | 1.0% | ||
| Q1 24 | 12.1% | — |
现金转化率CPRTGMAB
| Q4 25 | 1.33× | — | ||
| Q3 25 | 1.11× | — | ||
| Q2 25 | 1.72× | 1.04× | ||
| Q1 25 | 0.46× | — | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | 1.36× | — | ||
| Q2 24 | 1.30× | 2.16× | ||
| Q1 24 | 0.50× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRT
| Services | $952.1M | 82% |
| Other | $203.0M | 18% |
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
